EDITION
  • English
  • 中文
  • Bahasa
  • eCommerce
Thursday, March 23, 2023
uLearnMoney Subscription Events
No Result
View All Result
Money Compass

EDITIONS:

Media and partner organizations:

cmc bmc ulearnmoney mylife mcm asncommerce mcm
  • HOME
  • NEWS
    • Global Market News
    • Local Market News
    • Corporate News
    • PLC News
  • SPECIAL FEATURE
  • COMPASS
    • Financial
    • Investment
    • Start Up
    • Capital
    • Infographics & Quotes
  • MONEY TUBE
  • LIFESTYLE
  • PR NEWSWIRE
Subscription Newsletter
Money Compass
  • HOME
  • NEWS
    • Global Market News
    • Local Market News
    • Corporate News
    • PLC News
  • SPECIAL FEATURE
  • COMPASS
    • Financial
    • Investment
    • Start Up
    • Capital
    • Infographics & Quotes
  • MONEY TUBE
  • LIFESTYLE
  • PR NEWSWIRE
No Result
View All Result
中文 Bahasa eCommerce
Money Compass

Duopharma Announched gross profit of RM52.19 million

by moneycompass
February 17, 2020
in PLC News
Duopharma Announched gross profit of RM52.19 million

Source: Focus Malaysia

Share on FacebookShare on WhatsApp

KUALA LUMPUR, 14 February 2020 – In an announcement to Bursa Malaysia this evening Duopharma announched gross profit of RM52.19 million. Duopharma Biotech Berhad formerly known as CCM Duopharma Biotech Berhad announced a commendable set of unaudited financial results to close off a strong performance in 2019 with yearly net profit increasing 16 percent to touch RM55.27 million on higher revenue of RM576.46 million.

For its fourth quarter ended 31 December 2019, the Duopharma Biotech group posted gross profit of RM52.19 million (2018: 49.89 million) on an increased turnover of RM137.76 million (2018: RM115.63 million). After accounting for taxation and other costs, the group posted a net profit of RM12.03 million (2018: RM14.37 million).

For 2019, earnings per share came in at 8.25 sen, or close to a 14 percent increase from the 7.26 sen posted in the previous corresponding year.

The Duopharma Biotech Board of Directors has recommended a final dividend of 5.0 sen per share (2018: a final dividend of 4 sen per share) translating to RM34.22 million (2018: RM26.48 million). The Board has resolved that the Dividend Reinvestment Plan (DRP) approved by the shareholders in 2018 would apply to this dividend, if the dividend is approved by the shareholders at the Company’s forthcoming Annual General Meeting.

This higher final dividend follows on from the Group having paid an interim dividend of 1 sen per share (2018: 1.5 sen) equivalent to RM 6.8 million (2018: RM9.93 million) during the fourth quarter of 2019. Out of the total cash distribution, a total of RM5.3mil was converted into 4,276,658 new ordinary shares of the Company at the conversion price of RM 1.25 per ordinary share under the DRP.

Duopharma Biotech’s Group Managing Director, Leonard Ariff Abdul Shatar, attributed the Group’s strong performance to higher demand for the group’s pharmaceutical products from both the private and public health sectors.

“The Group’s net profit also improved significantly due to higher sales and also lower provision of inventories in FY 2019,” he said.

Leonard also believes that, barring any unforeseen circumstances, the Duopharma Biotech Group is expected to achieve a satisfactory set of results in FY2020.

“The recent budget 2020 has seen an increase of 6.6 percent in allocation for healthcare sector to
RM 30.6 billion,” said Leonard, adding that this is the highest ever allocation in Malaysian history.

He also shared that the Duopharma Biotech group has also been recently informed that contract periods for the supply of pharmaceutical and/or non-pharmaceutical products to hospitals, clinics and others under the Malaysian Government have been extended for twenty five months, commencing 1 December 2019 until 31 December 2021.

“The extension augurs well for the Group as it stabilises a significant portion of the Group’s revenue
for the said period,” he said. “What’s more, it enables the Group to mobilise our resources to intensify our foray into specialty products as one of our strategies moving forward to create a pool of niche products.” “In addition, based on the Ministry of Finance’s Economic Outlook 2020, global growth for our industry is forecasted to improve to 3.5 percent in 2020 from 3.2 percent in 2019. Growth in 2020 is expected to be supported by stronger GDP performance in emerging market and developing countries, and this includes Malaysia. Our GDP is anticipated to improve in 2020 relative to 2019.”

Leonard, Managing Director

He also believes that the Malaysian economic outlook is expected to remain resilient with domestic demand anchoring growth, despite the prolonged trade dispute between major economies, geopolitical tensions as well as volatility in the global financial and commodity markets. However, the ongoing Covid-19 (Novel Corona Virus) outbreak may result in disruption in global supply chain and may create uncertainties in the market which may dampen the global economic outlook.

 

Read More: SDO & UKM collaborate for Clinical Trial to Treat Fatty Liver Disease

Tags: Bursa MalaysiaDuopharma
Share1SendShareSendTweetShare
Previous Post

SDO & UKM collaborate for Clinical Trial to Treat Fatty Liver Disease

Next Post

UOB launched the United Global Income Allocator Fund

Related Posts

Zecon
PLC News

Zecon’s 576.4 million Right Issues of ICPS approved at EGM

22 Jul 2020
Sinotop
PLC News

Sinotop to acquire 51% in TAS for a total of RM13mil

11 Mar 2020
CCM Posted a Revenue of RM386.1million
PLC News

CCM Posted a Revenue of RM386.1million

21 Feb 2020

Discussion about this post

MOST POPULAR

  • Top 100 SMEs Defy Economic Headwinds to Post Triple-Digit Growth

    0 shares
    Share 0 Tweet 0
  • 10 Ways to Curb Overspending

    1 shares
    Share 0 Tweet 0
  • Dataxet Group Operation in Malaysia Wins Prestigious Brand Laureate Award for Sustainable Business

    0 shares
    Share 0 Tweet 0
  • 7 Reasons to Hold MICE Events at The Westin Grand Ballroom and Convention Center, Surabaya

    0 shares
    Share 0 Tweet 0
  • Leveraging MineSec’s SDK, NCCNet SoftPOS solution receives PCI CPoC certification

    0 shares
    Share 0 Tweet 0

MEMBERSHIP SUBSCRIPTION

Subscribe Now

Sign Up for Our Free Newsletters

Stay up-to-date with the latest personal wealth-related articles, breaking financial market news, and more.

Follow us on Social Media

News
Special Feature
Compass
Money Tube
Smart Lifestyle
Corporate Profile
Advertise
Subscriptions
Career
Contact Us
eLearning
Events
Privacy Policy
Terms of Use
Strategic Partners

Copyright © . Money Compass. All Rights Reserved.

Design and Development by Ant Internet Sdn Bhd

No Result
View All Result
  • HOME
  • NEWS
    • Global Market News
    • Local Market News
    • Corporate News
    • PLC News
  • SPECIAL FEATURE
  • COMPASS
    • Financial
    • Investment
    • Start Up
    • Capital
    • Infographics & Quotes
  • MONEY TUBE
  • LIFESTYLE
  • PR NEWSWIRE

© 2020 Money Compass

Career

SUBSCRIBE FREE NEWSLETTER